Navigation Links
Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
Date:10/7/2008

SAN DIEGO, Oct. 7 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) and AnGes MG, Inc., have signed a non-binding Letter of Intent indicating their mutual interest to license the development and marketing rights for Vical's pandemic influenza DNA vaccines in Japan to AnGes. AnGes plans to conduct due diligence on the pandemic influenza DNA vaccines, and both parties intend to negotiate terms and conditions potentially leading to a license, subject to completion of a mutually satisfactory definitive agreement.

Japan's geographic proximity to many of the avian influenza outbreaks in recent years puts the country at high risk for future outbreaks. The Japanese Ministry of Health, Labor and Welfare has estimated that the emergence of a new strain of influenza could lead to 13 to 25 million infections and 170,000 to 640,000 deaths in Japan. AnGes' experience in working with Vical's DNA delivery technology within the Japanese regulatory environment positions the company well to pursue further development in Japan based on Vical's recently announced preliminary Phase 1 H5N1 pandemic influenza data.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about a Letter of Intent to negotiate terms and conditions potentially leading to a license agreement with AnGes for development and marketing of pandemic influenza DNA vaccines in Japan, as well as Vical's focus, collaborative partners, and product candidates. Risks and uncertainties include whether we will be able to complete a mutually satisfactory definitive agreement with AnGes; whether preliminary H5N1 DNA vaccine Phase 1 clinical trial results will be confirmed upon further analysis or in larger studies; whether any product candidates under development by Vical or its collaborative partners will be shown to be safe and effective in clinical trials; the timing, nature and cost of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; whether Vical or its collaborative partners will succeed in marketing any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

Contact: Alan R. Engbring

(858) 646-1127

Website: http://www.vical.com


'/>"/>
SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vical to Present at UBS Global Life Sciences Conference
2. Society of Gynecologic Oncologists to Host Cervical Cancer Prevention Forum
3. Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System
4. Vical to Present at Upcoming Investor Conferences
5. Pioneer(R) Surgical Technology Announces First Human Implants of its NuNec(TM) Cervical Arthroplasty Device
6. Vical Announces News Release and Conference Call Schedule for First Quarter 2008 Financial Results
7. One4One Campaign to Raise $1 Million to Improve Cervical Cancer Education and Resources
8. Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
9. Vical to Present at Cowen and Company Health Care Conference
10. Vical to Present at BIO and BVGH Global Health Partnering Event
11. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 03, 2016 , ... Microbial ... microbiome impact grant award has been made to Dr. Renato Polimanti of Yale ... drinking on the oral microbiome. Grant proposals have been vetted by the company’s ...
(Date:12/2/2016)... Dec. 2, 2016 More than $4.3 million was ... Medals dinner ( DHMD ). The gala was held at the ... York City and honored Alan Alda ... to health and medicine and the public understanding of science. ... 2006, the event has raised $40 million for the Laboratory,s ...
(Date:12/2/2016)... , Dec 2, 2016 Research and ... "Nanobiotechnology Applications, Markets and Companies" to their offering. ... , , ... by the pharmaceutical and biotechnology industries is anticipated. Nanotechnology will ... formulations for optimal delivery to diagnostic applications in clinical trials. ...
(Date:12/2/2016)... , ... December 01, 2016 , ... ... Science Symposium (CSS) and the popularity of US Single Day Events (SDE) to ... in early Summer 2018, in Raleigh, NC. Topics of the pharmaceutical and life ...
Breaking Biology Technology:
(Date:6/15/2016)... York , June 15, 2016 ... new market report titled "Gesture Recognition Market by Application ... Forecast, 2016 - 2024". According to the report, the  ... 11.60 billion in 2015 and is estimated to ... USD 48.56 billion by 2024.  Increasing ...
(Date:6/7/2016)... , June 7, 2016  Syngrafii Inc. ... a business relationship that includes integrating Syngrafii,s patented ... branch project. This collaboration will result in greater ... the credit union, while maintaining existing document workflow ... http://photos.prnewswire.com/prnh/20160606/375871LOGO ...
(Date:6/2/2016)... --  The Weather Company , an IBM Business (NYSE: ... in which consumers will be able to interact with IBM ... voice or text and receive relevant information about the product ... have long sought an advertising solution that can create a ... and valuable; and can scale across millions of interactions and ...
Breaking Biology News(10 mins):